statistiche ricercatore

Continente	#
NA - Nord America	923
EU - Europa	743
AS - Asia	694
Continente sconosciuto - Info sul continente non disponibili	106
SA - Sud America	63
AF - Africa	18
OC - Oceania	6
Totale	2.553

Nazione	#
US - Stati Uniti d'America	878
IT - Italia	260
CN - Cina	212
SG - Singapore	165
GB - Regno Unito	126
DE - Germania	107
HK - Hong Kong	77
BD - Bangladesh	69
SE - Svezia	53
VN - Vietnam	48
BR - Brasile	44
RU - Federazione Russa	40
FR - Francia	39
IN - India	35
CA - Canada	28
NL - Olanda	26
FI - Finlandia	23
JP - Giappone	19
IE - Irlanda	15
CI - Costa d'Avorio	14
ID - Indonesia	13
PL - Polonia	13
TR - Turchia	12
BE - Belgio	11
KR - Corea	9
PH - Filippine	8
TW - Taiwan	7
AU - Australia	6
EC - Ecuador	6
ES - Italia	6
AT - Austria	5
UA - Ucraina	5
AR - Argentina	4
MX - Messico	4
UZ - Uzbekistan	4
CH - Svizzera	3
CL - Cile	3
CO - Colombia	3
JM - Giamaica	3
AP - ???statistics.table.value.countryCode.AP???	2
BB - Barbados	2
CR - Costa Rica	2
DO - Repubblica Dominicana	2
GR - Grecia	2
HR - Croazia	2
HU - Ungheria	2
IQ - Iraq	2
LT - Lituania	2
SV - El Salvador	2
TH - Thailandia	2
UY - Uruguay	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
CU - Cuba	1
GT - Guatemala	1
IL - Israele	1
IR - Iran	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LU - Lussemburgo	1
LV - Lettonia	1
MA - Marocco	1
MG - Madagascar	1
MY - Malesia	1
NG - Nigeria	1
NP - Nepal	1
OM - Oman	1
PE - Perù	1
PK - Pakistan	1
PS - Palestinian Territory	1
RO - Romania	1
SA - Arabia Saudita	1
ZA - Sudafrica	1
Totale	2.449

Nome	#
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)	573
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients	320
Current and Emerging Treatment Options for Patients with Relapsed Myeloma	312
Immunotherapeutic early-phase clinical trials and malignant gliomas : A single-center experience and comprehensive immunophenotyping of circulating leukocytes	233
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1	219
Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety : a multicenter Italian retrospective study	216
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors	193
Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series	191
Choosing treatment options for patients with relapsed/refractory multiple myeloma	181
Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience	75
Prognostic factors and outcome of HER2+ breast cancer with CNS metastases	37
null	3
Totale	2.553

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	208	0	0	0	17	17	19	21	30	36	20	11	37
2022/2023	199	24	28	22	20	17	32	2	7	23	5	13	6
2023/2024	182	2	9	11	8	45	6	16	22	5	12	22	24
2024/2025	384	14	32	11	52	20	20	12	41	20	34	42	86
2025/2026	862	79	60	106	62	67	36	127	16	63	53	101	92
2026/2027	224	67	58	55	44	0	0	0	0	0	0	0	0
Totale													2.553

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca